Endometrial transitional cell carcinoma
diseaseOn this page
Summary
Endometrial transitional cell carcinoma (MONDO:0002832) is a cancer and 5 clinical trials. Top therapeutic interventions include nintedanib, brivanib alaninate, and dalantercept. A subtype of endometrial carcinoma — broader associated-gene and molecular evidence is on the parent page (see Disease family below).
At a glance
- Classification: Cancer
- Clinical trials: 5
Clinical features
No curated clinical features (Orphanet) for this disease.
Identifiers
Disease identifiers
| Field | Value |
|---|---|
| Canonical name | endometrial transitional cell carcinoma |
| Mondo ID | MONDO:0002832 |
| DOID | DOID:4005 |
| NCIT | C40154 |
| UMLS | C1516864 |
| MedGen | 273232 |
| GARD | 0023259 |
| Is cancer (heuristic) | yes |
Also known as: endometrial transitional cell carcinoma
Disease family
This is a subtype of endometrial carcinoma. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.
Classification path: disease by etiologic mechanism › cancer or benign tumor › neoplastic disease or syndrome › neoplasm › cancer › reproductive system cancer › female reproductive organ cancer › uterine cancer › uterine carcinoma › endometrial carcinoma › endometrial transitional cell carcinoma
Related subtypes (6): uterine corpus endometrial carcinoma, endometrium carcinoma in situ, endometrium adenocarcinoma, endometrial small cell carcinoma, endometrial squamous cell carcinoma, endometrial undifferentiated carcinoma
Genetics & variants
GWAS landscape
No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.
Variant details and genetic-evidence tiers
No tiered GWAS variants or ClinVar records for this disease.
Genes & proteins
No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).
Function
No pathway enrichment — requires an associated-gene cohort.
Therapeutics
No druggable-target or therapeutic data for this disease’s cohort.
Clinical trials & evidence
Clinical trials
Clinical trials: 5.
Phase distribution (across all retrieved trials)
| Phase | Trials |
|---|---|
| PHASE2 | 4 |
| PHASE1 | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT02834013 | PHASE2 | ACTIVE_NOT_RECRUITING | Nivolumab and Ipilimumab in Treating Patients With Rare Tumors |
| NCT00888173 | PHASE2 | COMPLETED | Brivanib Alaninate in Treating Patients With Recurrent or Persistent Endometrial Cancer |
| NCT01225887 | PHASE2 | COMPLETED | Nintedanib in Treating Patients With Recurrent or Persistent Endometrial Cancer |
| NCT01642082 | PHASE2 | COMPLETED | Dalantercept in Treating Patients With Recurrent or Persistent Endometrial Cancer |
| NCT01440998 | PHASE1 | COMPLETED | Dasatinib, Paclitaxel, and Carboplatin in Treating Patients With Stage III-IV or Recurrent Endometrial Cancer |
Drugs tested across these trials (top 30)
| Molecule | Max phase | Trials referencing |
|---|---|---|
| NINTEDANIB | 4 | 1 |
| BRIVANIB ALANINATE | 3 | 1 |
| DALANTERCEPT | 3 | 1 |
Related Atlas pages
- Drugs: Nintedanib, Brivanib Alaninate, Dalantercept